{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-110287","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2024-10-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.815750+00:00","generated_at":"2026-05-30T12:24:16.305998+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gain Therapeutics regains Nasdaq compliance with $50M market value requirement","bullets":["Received Nasdaq letter on Oct 21, 2024 confirming regained compliance with MVLS Requirement.","Previously non-compliant as of July 11, 2024; had until Jan 7, 2025 to cure.","Compliance now achieved; matter closed with no further action needed.","Regained compliance ensures continued listing on The Nasdaq Global Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-110287","json":"https://secwatch.observer/filing/0001104659-24-110287.json","markdown":"https://secwatch.observer/filing/0001104659-24-110287.md","text":"https://secwatch.observer/filing/0001104659-24-110287.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000110465924110287/0001104659-24-110287-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000110465924110287/tm2426597d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T12:24:16.305998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}